How often is Erbitux given?
How to use Erbitux Vial. Cetuximab is given by injection into a vein as directed by your doctor, usually once every week or every 2 weeks by a healthcare professional. Another drug (such as diphenhydramine) may be given before you receive cetuximab to lessen the chance of certain side effects.
How do you administer Erbitux?
Erbitux 5 mg/mL is administered intravenously with an infusion pump, gravity drip or a syringe pump (for handling instructions, see section 6.6). The initial dose should be given slowly and speed of infusion must not exceed 5 mg/min (see section 4.4). The recommended infusion period is 120 minutes.
How long can you stay on Erbitux?
Median overall survival in wild-type KRAS patients was 24.9 months for the Erbitux and chemotherapy group but only 21 months for patients receiving chemotherapy alone.
How is Erbitux used to treat colorectal cancer?
ERBITUX is approved for the treatment of certain patients who have colorectal cancer that has spread to other parts of the body. Only patients whose tumors are KRAS wild-type (which means they have a KRAS mutation-negative gene), and whose tumors have a protein called epidermal growth factor receptor (EGFR), should receive ERBITUX.
How to prepare for the administration of Erbitux?
Preparation for Administration Do not administer Erbitux as an intravenous push or bolus. Administer via infusion pump or syringe pump. Do not exceed an infusion rate of 10 mg/min. Administer through a low protein binding 0.22-micrometer in-line filter.
Are there any side effects of taking Erbitux?
Serious allergic reactions due to ERBITUX therapy occurred in 2.2% of patients receiving ERBITUX during clinical studies; 1 patient died. The risk of anaphylactic reactions may be increased in patients with a history of tick bites, red meat allergy, or in the presence of certain antibodies which can react to ERBITUX.
When to use Erbitux in combination with FOLFIRI?
Erbitux is indicated for the treatment of K-Ras wild-type, epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal cancer (mCRC) as determined by an FDA-approved test [see Dosage and Administration (2.2)]: in combination with FOLFIRI (irinotecan, fluorouracil, leucovorin) for first-line treatment,
